The library / Topic
Medicine
Medicine covers peptides that regulators have approved or that are in large trials. Here the evidence is strongest, because approved drugs come with labels and trial data, and investigational drugs come with registered protocols. The articles explain what those trials measured, why doses are raised step by step, and how a label differs from a figure copied onto a forum chart.
Begin with how a peptide becomes a medicine, then read why retatrutide trials start low and escalate. Sermorelin vs tesamorelin compares a product discontinued in 2008 with an approved one, and the CagriSema and cagrilintide guide reports what the trial program used. None of it is a prescription.
Peptides as Homing Devices on a New Front in Cancer Care
Some of the most promising uses of peptides in oncology are not about killing cancer directly, but about finding it, marking it and training the immune system to notice it.
ReadHow a Peptide Becomes a Medicine From Lab Bench to Pharmacy Shelf
Most candidates fail. Here is the long road every approved peptide drug has travelled, and what the "research use only" label really tells you.
ReadCagriSema Stack and Cagrilintide Peptide Dosage Guide
Which cagrilintide doses were tested alone and with semaglutide, how CagriSema was escalated, and why no trial has paired cagrilintide with tirzepatide.
ReadRetatrutide Dosage Clicks and the Trial Dosage Chart
A chart of every retatrutide dose level tested in trials, how side effects rose with dose, and why counting pen clicks does not apply to this investigational drug.
ReadRetatrutide Starting Dose and Why Trials Escalate Slowly
Why retatrutide trials began at 2 mg weekly, what phase 2 learned by comparing two first doses and why incretin drugs are raised step by step.
ReadDo Sermorelin Tablets and Pills Actually Work
Why digestion is a problem for sermorelin tablets, what absorption data exist for non injected routes and what studies show for injected sermorelin.
ReadSermorelin vs Tesamorelin and Which Growth Hormone Peptide Fits the Evidence
Two GHRH analogues with one target and very different records. Compare structure, approval history, ipamorelin's place and what forum stacking claims miss.
Read